Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) announced on December 31, 2025 that its Compensation Committee approved inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
On December 30, 2025 the committee granted restricted stock awards to seven new employees totaling up to 79,584 restricted shares. The awards vest in three equal annual instalments (one-third each year) and will be fully vested on the third anniversary of the grant date, subject to each employee’s continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – ABEO
In the Dec 31 session, ABEO gained 1.74%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Executive appointment | Positive | -5.2% | New Chief Business Officer appointed to lead strategy and business development. |
| Dec 11 | Commercial expansion | Positive | +0.9% | New Qualified Treatment Center activated for ZEVASKYN in Texas. |
| Dec 08 | First patient treated | Positive | +5.3% | First commercial ZEVASKYN patient treated with additional patients scheduled. |
| Dec 01 | Inducement grants | Neutral | -5.7% | Inducement restricted stock awards granted to new non-executive hires. |
| Nov 12 | Earnings and updates | Positive | +18.5% | Q3 results with strong cash, lower net loss, and ZEVASKYN launch prep. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational and earnings updates often coincided with gains (e.g., Q3 results, first ZEVASKYN treatment), while a leadership appointment and a prior inducement grant date were followed by declines, indicating mixed reactions to corporate updates.
Over the last two months, Abeona reported several milestones. On Nov 12, 2025, Q3 results highlighted $207.5M in cash and a narrower net loss, with the stock rising 18.47%. Subsequent ZEVASKYN commercialization updates, including the first patient treatment on Dec 8 and a new Texas treatment center on Dec 11, saw modest to solid gains. In contrast, management and inducement grant announcements on Dec 1 and Dec 15 were followed by mid‑single‑digit declines, framing today’s new inducement grants within a pattern of mixed responses to corporate and HR news.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock financial
grant date financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On December 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 79,584 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com